Small molecule, API biz to be growth drivers for company: Kiran Mazumdar Shaw, Biocon

New Drug Approvals

"We have focused on creating key growth drivers and have structured the company along those growth drivers," says Kiran Mazumdar Shaw. (BCCL)“We have focused on creating key growth drivers and have structured the company along those growth drivers,” says Kiran Mazumdar Shaw. (BCCL)…………. owner BIOCON

MY, DR AMC  COMMENTS- BIOCON GREAT PERFORMANCE, U ARE EVERYWHERE

 

Kiran Mazumdar Shaw: We have focused on creating key growth drivers and have structured the company along those growth drivers. These growth drivers are beginning to deliver very strongly for us.

The first is our small molecule business vertical, which is about our historic statins and immunosuppressant’s API business. This particular vertical going forward is envisioned to go up the value chain along an ANDA path and we believe that will improve the quality of earnings in this particular vertical, which for a long time was under pressure because of commoditisation of statins.http://economictimes.indiatimes.com/opinion/interviews/small-molecule-api-biz-to-be-growth-drivers-for-company-kiran-mazumdar-shaw-biocon/articleshow/21975113.cms

View original post

Advertisements

Small molecule, API biz to be growth drivers for company: Kiran Mazumdar Shaw, Biocon

New Drug Approvals

"We have focused on creating key growth drivers and have structured the company along those growth drivers," says Kiran Mazumdar Shaw. (BCCL)“We have focused on creating key growth drivers and have structured the company along those growth drivers,” says Kiran Mazumdar Shaw. (BCCL)…………. owner BIOCON

MY, DR AMC  COMMENTS- BIOCON GREAT PERFORMANCE, U ARE EVERYWHERE

 

Kiran Mazumdar Shaw: We have focused on creating key growth drivers and have structured the company along those growth drivers. These growth drivers are beginning to deliver very strongly for us.

The first is our small molecule business vertical, which is about our historic statins and immunosuppressant’s API business. This particular vertical going forward is envisioned to go up the value chain along an ANDA path and we believe that will improve the quality of earnings in this particular vertical, which for a long time was under pressure because of commoditisation of statins.http://economictimes.indiatimes.com/opinion/interviews/small-molecule-api-biz-to-be-growth-drivers-for-company-kiran-mazumdar-shaw-biocon/articleshow/21975113.cms

View original post

ATORVASTATIN SYNTHESIS

New Drug Approvals

File:Atorvastatin2D.svg

atorvastatin

File:Atorvastatin3Dan.gif

Atorvastatin (INN/əˌtɔrvəˈstætən/, marketed by Pfizer as a calcium salt under the trade name Lipitor,[1] is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. Like all statins, atorvastatin works by inhibitingHMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.

Atorvastatin was first synthesized in 1985 by Bruce Roth of Parke-Davis Warner-Lambert Company (since acquired by Pfizer). The best selling drug in pharmaceutical history, sales of Lipitor since it was approved in 1996 exceed US$125 billion, and the drug has topped the list of best-selling branded pharmaceuticals in the world for nearly a decade.[2] When Pfizer’s patent on…

View original post 939 more words

ATORVASTATIN SYNTHESIS

New Drug Approvals

File:Atorvastatin2D.svg

atorvastatin

File:Atorvastatin3Dan.gif

Atorvastatin (INN/əˌtɔrvəˈstætən/, marketed by Pfizer as a calcium salt under the trade name Lipitor,[1] is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. Like all statins, atorvastatin works by inhibitingHMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.

Atorvastatin was first synthesized in 1985 by Bruce Roth of Parke-Davis Warner-Lambert Company (since acquired by Pfizer). The best selling drug in pharmaceutical history, sales of Lipitor since it was approved in 1996 exceed US$125 billion, and the drug has topped the list of best-selling branded pharmaceuticals in the world for nearly a decade.[2] When Pfizer’s patent on…

View original post 939 more words

Small molecule, API biz to be growth drivers for company: Kiran Mazumdar Shaw, Biocon

New Drug Approvals

"We have focused on creating key growth drivers and have structured the company along those growth drivers," says Kiran Mazumdar Shaw. (BCCL)“We have focused on creating key growth drivers and have structured the company along those growth drivers,” says Kiran Mazumdar Shaw. (BCCL)…………. owner BIOCON

MY, DR AMC  COMMENTS- BIOCON GREAT PERFORMANCE, U ARE EVERYWHERE

 

Kiran Mazumdar Shaw: We have focused on creating key growth drivers and have structured the company along those growth drivers. These growth drivers are beginning to deliver very strongly for us.

The first is our small molecule business vertical, which is about our historic statins and immunosuppressant’s API business. This particular vertical going forward is envisioned to go up the value chain along an ANDA path and we believe that will improve the quality of earnings in this particular vertical, which for a long time was under pressure because of commoditisation of statins.http://economictimes.indiatimes.com/opinion/interviews/small-molecule-api-biz-to-be-growth-drivers-for-company-kiran-mazumdar-shaw-biocon/articleshow/21975113.cms

View original post

Small molecule, API biz to be growth drivers for company: Kiran Mazumdar Shaw, Biocon

New Drug Approvals

"We have focused on creating key growth drivers and have structured the company along those growth drivers," says Kiran Mazumdar Shaw. (BCCL)“We have focused on creating key growth drivers and have structured the company along those growth drivers,” says Kiran Mazumdar Shaw. (BCCL)…………. owner BIOCON

MY, DR AMC  COMMENTS- BIOCON GREAT PERFORMANCE, U ARE EVERYWHERE

 

Kiran Mazumdar Shaw: We have focused on creating key growth drivers and have structured the company along those growth drivers. These growth drivers are beginning to deliver very strongly for us.

The first is our small molecule business vertical, which is about our historic statins and immunosuppressant’s API business. This particular vertical going forward is envisioned to go up the value chain along an ANDA path and we believe that will improve the quality of earnings in this particular vertical, which for a long time was under pressure because of commoditisation of statins.http://economictimes.indiatimes.com/opinion/interviews/small-molecule-api-biz-to-be-growth-drivers-for-company-kiran-mazumdar-shaw-biocon/articleshow/21975113.cms

View original post